Role of Intact Proinsulin in Diagnosis and Treatment of Type 2 Diabetes Mellitus
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Insulin resistance in patients with type 2 diabetes is associated with an increased risk of cardiovascular events. While this can be partly explained by an impairment of direct insulin action on the endothelial cell, an independent contribution can be assigned also to the secretory dysfunction of the beta-cell. If the demand for insulin triggered by insulin resistance is arriving at a certain threshold, an insufficiency of the cleavage capacity of beta-cell carboxypeptidase H leads to an increased secretion of intact proinsulin in addition to the desired insulin molecule. Proinsulin, however, has been demonstrated to be an independent cardiovascular risk factor by stimulating plasminogen activator inhibitor-1 secretion and blocking fibrinolysis. A recently introduced intact proinsulin assay is able to distinguish between intact proinsulin and its specific and non-specific cleavage products. This assay allows for a pathophysiological staging of type 2 diabetes based on beta-cell secretion. It could be confirmed by a large epidemiological study (IRIS-2, 4,265 patients) that intact proinsulin is a highly specific marker for insulin resistance. It could also be shown in other studies that successful resistance treatment with insulin or glitazones led to a decrease in elevated proinsulin levels and, thus, to a decrease of cardiovascular risk, while the levels remained high during sulfonylurea therapy. Therefore, patients with increased fasting intact proinsulin values should be treated with a therapy focusing on insulin resistance. Assessment of beta-cell function by determination of intact proinsulin may facilitate the selection of the most promising therapy and may also serve to monitor treatment success in the further course of the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ward, W. K., LaCava, E. C., Paquette, T. L., Beard, J. C., Wallum, B. J., & Porte, D. (1987) · Diabetologia · doi:10.1007/bf00296991 · Cited by 275
Insulin resistance and coronary artery disease
Bressler, P., Bailey, S. R., Matsuda, M., & DeFronzo, R. A. (1996) · Diabetologia · doi:10.1007/s001250050581 · Cited by 226
Kahn, S. E., & Halban, P. A. (1997) · Diabetes · doi:10.2337/diabetes.46.11.1725 · Cited by 221
Kahn, S. E., & Halban, P. A. (1997) · Diabetes · doi:10.2337/diab.46.11.1725 · Cited by 221
Reaven, G. M., Chen, Y. D., Hollenbeck, C. B., Sheu, W. H., Ostrega, D., & Polonsky, K. S. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.76.1.8421101 · Cited by 214
Yoshioka, N., Kuzuya, T., Matsuda, A., Taniguchi, M., & Iwamoto, Y. (1988) · Diabetologia · doi:10.1007/bf02341503 · Cited by 175
Disproportionately Elevated Proinsulin in Pima Indians with Noninsulin-Dependent Diabetes Mellitus*
SAAD, M. F., KAHN, S. E., NELSON, R. G., PETTITT, D. J., KNOWLER, W. C., SCHWARTZ, M. W., KOWALYK, S., BENNETT, P. H., & PORTE, D. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-70-5-1247 · Cited by 167
Proinsulin as a marker for the development of NIDDM in Japanese-American men
Kahn, S. E., Leonetti, D. L., Prigeon, R. L., Boyko, E. J., Bergstrom, R. W., & Fujimoto, W. Y. (1995) · Diabetes · doi:10.2337/diabetes.44.2.173 · Cited by 138
Cited by
Exenatide Versus Glibenclamide in Patients with Diabetes
Derosa, G., Maffioli, P., Salvadeo, S. A. T., Ferrari, I., Ragonesi, P. D., Querci, F., Franzetti, I. G., Gadaleta, G., Ciccarelli, L., Piccinni, M. N., et al. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0141 · Cited by 125
Derosa, G., Franzetti, I. G., Querci, F., Carbone, A., Ciccarelli, L., Piccinni, M. N., Fogari, E., & Maffioli, P. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03699.x · Cited by 70
La Vignera, S., Cannarella, R., Galvano, F., Grillo, A., Aversa, A., Cimino, L., Magagnini, C. M., Mongioì, L. M., Condorelli, R. A., & Calogero, A. E. (2021) · Endocrine · doi:10.1007/s12020-020-02518-8 · Cited by 36
Breuer, T. G. K., Menge, B. A., Banasch, M., Uhl, W., Tannapfel, A., Schmidt, W. E., Nauck, M. A., & Meier, J. J. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0330 · Cited by 20
Pfützner, A., Hermanns, I., Ramljak, S., Demircik, F., Pfützner, A. H., Kann, P. H., & Weber, M. M. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815607862 · Cited by 12
Self-citation
Metadata
- Authors
- Pfützner, A., Pfützner, A. H., Larbig, M., & Forst, T.
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2004-06
- Volume
- 6
- Issue
- 3
- Pages
- 405-412
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W2175004488
- Cited by
- 52
- References
- 8
- FWCI
- 1.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Role of Intact Proinsulin in Diagnosis and Treatment of Type 2 Diabetes Mellitus. https://app.cochat.ai/papers/10.1089/152091504774198124
- The paper
- Pfützner, A., Pfützner, A. H., Larbig, M., & Forst, T. (2004). Role of Intact Proinsulin in Diagnosis and Treatment of Type 2 Diabetes Mellitus. Diabetes Technology & Therapeutics. https://doi.org/10.1089/152091504774198124
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.